Oxford BioTherapeutics and Bristol Myers Squibb Partner to Develop Next-Generation T-Cell Engagers

Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours 

Oxford BioTherapeutics is a clinical-stage oncology company focused on the discovery and development of immuno-oncology and antibody drug conjugate-based therapies enabled by its OGAP.OBT will leverage its proprietary OGAP to help verify target discovery and validation platform, to identify novel, tumour-selective targets for solid cancers, and generate next-generation T-cell engager molecules. 

It aims to broaden access to precision oncology by equipping industry partners with the tools and insights needed to deliver novel, effective cancer therapies to more patients, more quickly. 

According to Towards Healthcare, the bispecific T cell engagers market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 10.61 billion in 2026 to approximately USD 49.73 billion by 2035, representing a compound annual growth rate (CAGR) of 18.72% from 2026 to 2035. Growth is driven by the increasing prevalence of blood cancers and solid tumors, which fuel demand for targeted immunotherapies. With technological innovations in bispecific antibody engineering, stability, efficacy, and safety profiles.  

Partnership to develop next generation T cell engagers for solid tumours 

PhD, Chief Executive Officer of OBT, Christian Rohlff, said, collaborating with Bristol Myers Squibb, a global leader in oncology, represents an important milestone for OBT and underscores the momentum behind our partnerships with leading pharmaceutical companies. 

This new partnership builds on the proven strength of our platform to identify and validate highly differentiated, tumour-selective targets and reflects the growing confidence in our ability to translate that science into development-ready therapeutic candidates.  

By combining OGAP Verify’s discovery and validation capabilities with Bristol Myers Squibb’s expertise in translating oncology into clinical and commercial outcomes, they said that we are confident that together we can advance a new generation of innovative cancer therapies that have the potential to make a meaningful difference for patients. 

A recent report by Towards Healthcare highlights that the bispecific T cell engagers market is witnessing growth due to the market being supported by technological advancements, strategic collaborations between biotech firms and large pharmaceutical companies, and advancements in antibody engineering, which are accelerating product commercialization and manufacturing scalability.  

It focuses on personalized medicine, rising cancer incidence worldwide, and improved reimbursement frameworks in major markets such as the U.S. and Europe, which are contributing to market momentum.